0000899243-22-004571.txt : 20220203
0000899243-22-004571.hdr.sgml : 20220203
20220203161559
ACCESSION NUMBER: 0000899243-22-004571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220201
FILED AS OF DATE: 20220203
DATE AS OF CHANGE: 20220203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harding Thomas C.
CENTRAL INDEX KEY: 0001834833
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 22588483
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-01
0
0001466301
Clovis Oncology, Inc.
CLVS
0001834833
Harding Thomas C.
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2022-02-01
4
M
0
1563
A
6958
D
Common Stock
2022-02-02
4
S
0
943
1.9397
D
6015
D
Common Stock
2022-02-01
4
M
0
1813
A
7828
D
Common Stock
2022-02-02
4
S
0
1094
1.9396
D
6734
D
Common Stock
2022-02-01
4
M
0
182
A
1733
I
By wife
Common Stock
2022-02-02
4
S
0
81
1.9396
D
1652
I
By wife
Restricted Stock Units
2022-02-01
4
M
0
1563
0.00
D
Common Stock
1563
6250
D
Restricted Stock Units
2022-02-01
4
M
0
1813
0.00
D
Common Stock
1813
14500
D
Restricted Stock Units
2022-02-01
4
M
0
182
0.00
D
Common Stock
182
1450
I
By wife
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On January 31, 2020, the reporting person's wife was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Senior Vice President and Chief Scientific Officer
/s/ Thomas Harding
2022-02-02